Literature DB >> 9361038

Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.

P Vehmanen1, L S Friedman, H Eerola, M McClure, B Ward, L Sarantaus, T Kainu, K Syrjäkoski, S Pyrhönen, O P Kallioniemi, T Muhonen, M Luce, T S Frank, H Nevanlinna.   

Abstract

One hundred breast and breast-ovarian cancer families identified at the Helsinki University Central Hospital in southern Finland and previously screened for mutations in the BRCA2 gene were now analyzed for mutations in the BRCA1 gene. The coding region and splice boundaries of BRCA1 were analyzed by protein truncation test (PTT) and heteroduplex analysis (HA)/SSCP in all 100 families, and 70 were also screened by direct sequencing. Contrary to expectations based on Finnish population history and strong founder effects in several monogenic diseases in Finland, a wide spectrum of BRCA1 and BRCA2 mutations was found. In the BRCA1 gene, 10 different protein truncating mutations were found each in one family. Six of these are novel Finnish mutations and four have been previously found in other European populations. Six different BRCA2 mutations were found in 11 families. Altogether only 21% of the breast cancer families were accounted for by mutations in these two genes. Linkage to both chromosome 17q21 (BRCA1) and 13q12 (BRCA2) was also excluded in a subset of seven mutation-negative families with four or more cases of breast or ovarian cancer. These data indicate that additional breast and breast-ovarian cancer susceptibility genes are likely to be important in Finland.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9361038     DOI: 10.1093/hmg/6.13.2309

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  35 in total

1.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

Authors:  Pia Vahteristo; Jirina Bartkova; Hannaleena Eerola; Kirsi Syrjäkoski; Salla Ojala; Outi Kilpivaara; Anitta Tamminen; Juha Kononen; Kristiina Aittomäki; Päivi Heikkilä; Kaija Holli; Carl Blomqvist; Jiri Bartek; Olli-P Kallioniemi; Heli Nevanlinna
Journal:  Am J Hum Genet       Date:  2002-07-28       Impact factor: 11.025

2.  Frequency of 5382insC mutation of BRCA1 gene among breast cancer patients: an experience from Eastern India.

Authors:  Abhijit Chakraborty; Ashis Mukhopadhyay; Deboshree Bhattacharyya; Chinmoy Kr Bose; Keya Choudhuri; Soma Mukhopadhyay; Jayasri Basak
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

3.  Screening of HELQ in breast and ovarian cancer families.

Authors:  Liisa M Pelttari; Laura Kinnunen; Johanna I Kiiski; Sofia Khan; Carl Blomqvist; Kristiina Aittomäki; Heli Nevanlinna
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

4.  Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus.

Authors:  T Kainu; S H Juo; R Desper; A A Schaffer; E Gillanders; E Rozenblum; D Freas-Lutz; D Weaver; D Stephan; J Bailey-Wilson; O P Kallioniemi; M Tirkkonen; K Syrjäkoski; T Kuukasjärvi; P Koivisto; R Karhu; K Holli; A Arason; G Johannesdottir; J T Bergthorsson; H Johannsdottir; V Egilsson; R B Barkardottir; O Johannsson; K Haraldsson; T Sandberg; E Holmberg; H Grönberg; H Olsson; A Borg; P Vehmanen; H Eerola; P Heikkila; S Pyrhönen; H Nevanlinna
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

5.  Testing for hereditary breast and ovarian cancer in the southeastern United States.

Authors:  A Miron; J M Schildkraut; B K Rimer; E P Winer; C Sugg Skinner; P A Futreal; D Culler; B Calingaert; S Clark; P Kelly Marcom; J D Iglehart
Journal:  Ann Surg       Date:  2000-05       Impact factor: 12.969

6.  Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility.

Authors:  Yen Ling Low; Yuqing Li; Keith Humphreys; Anbupalam Thalamuthu; Yi Li; Hatef Darabi; Sara Wedrén; Carine Bonnard; Kamila Czene; Mark M Iles; Tuomas Heikkinen; Kristiina Aittomäki; Carl Blomqvist; Heli Nevanlinna; Per Hall; Edison T Liu; Jianjun Liu
Journal:  PLoS Genet       Date:  2010-07-01       Impact factor: 5.917

7.  Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene.

Authors:  Jirina Bartkova; Johanna Tommiska; Lenka Oplustilova; Kirsimari Aaltonen; Anitta Tamminen; Tuomas Heikkinen; Martin Mistrik; Kristiina Aittomäki; Carl Blomqvist; Päivi Heikkilä; Jiri Lukas; Heli Nevanlinna; Jiri Bartek
Journal:  Mol Oncol       Date:  2008-10-07       Impact factor: 6.603

8.  Overestimation of hereditary breast cancer risk.

Authors:  J D Iglehart; A Miron; B K Rimer; E P Winer; D Berry; M J Shildkraut
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

9.  BRCA2 mutations in 154 finnish male breast cancer patients.

Authors:  Kirsi Syrjäkoski; Tuula Kuukasjärvi; Kati Waltering; Karin Haraldsson; Anssi Auvinen; Ake Borg; Tommi Kainu; Olli-P Kallioniemi; Pasi A Koivisto
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

10.  A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population.

Authors:  Grazia Palomba; Angela Loi; Antonella Uras; Patrizia Fancello; Giovanna Piras; Attilio Gabbas; Antonio Cossu; Mario Budroni; Antonio Contu; Francesco Tanda; Antonio Farris; Sandra Orrù; Carlo Floris; Marina Pisano; Mario Lovicu; Maria Cristina Santona; Gennaro Landriscina; Laura Crisponi; Giuseppe Palmieri; Maria Monne
Journal:  BMC Cancer       Date:  2009-07-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.